- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.11. | HEXIMA LIMITED: AGM - Results of Meeting | - | ASX | ||
| 27.11. | HEXIMA LIMITED: AGM - Chair's Address - The Path Forward | 1 | ASX | ||
| HEXIMA Aktie jetzt für 0€ handeln | |||||
| 31.10. | HEXIMA LIMITED: Business Activity Statement & Appendix 4C - Sep-2025 Qtr | - | ASX | ||
| 24.10. | HEXIMA LIMITED: Annual General Meeting & Proxy Form | - | ASX | ||
| 15.10. | HEXIMA LIMITED: Long Term Suspended Entities | - | ASX | ||
| 19.09. | HEXIMA LIMITED: Annual General Meeting & Director Nomination | - | ASX | ||
| 29.08. | HEXIMA LIMITED: 2025 Annual Report | - | ASX | ||
| 29.08. | HEXIMA LIMITED: Appendix 4G | - | ASX | ||
| 29.08. | HEXIMA LIMITED: Appendix 4E | - | ASX | ||
| 31.07. | HEXIMA LIMITED: Business Activity Statement & Appendix 4C - Jun-2025 Qtr | - | ASX | ||
| 16.07. | HEXIMA LIMITED: Long Term Suspended Entities | - | ASX |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 247,99 | +30,54 % | Morning Market Movers: SMX, Praxis Precision Medicines, Polyrizon, Rubrik, Inc. See Big Swings | HONG KONG (dpa-AFX) - At 7:50 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VERA THERAPEUTICS | 44,900 | +5,37 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| COGENT BIOSCIENCES | 38,770 | -1,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) | ||
| ARCUTIS BIOTHERAPEUTICS | 31,200 | +0,13 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| NUVALENT | 109,60 | +2,56 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| QIAGEN | 40,405 | -0,02 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 76,75 | +1,66 % | Apogee Therapeutics: Noch ein sharedealsPlus-Verdoppler! | Im Juli hatten wir mit der Aktie von Apogee Therapeutics einen Verdopplungskandidaten identifiziert. Jetzt, keine fünf Monate später, konnte die Aktie tatsächlich mehr als +100% zulegen. Ein weiterer... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,850 | -1,29 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,63 | +0,13 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,710 | -4,27 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 38,500 | -1,05 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,470 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 39,830 | +4,13 % | Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data | ||
| CG ONCOLOGY | 43,300 | -3,20 % | CG Oncology Inc.: New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer | ||
| IMMUNOVANT | 22,840 | -0,31 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen |
Das Unternehmen HEXIMA LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEXIMA LIMITED finden Sie auf Wallstreet Online.